 |
|
|
| |
Clinical Pharmacokinetics and Safety of Orally Administered VH4004280 (VH-280), a Novel HIV-1 Capsid Inhibitor, in Adults Without HIV
|
| |
| |
25th Intl AIDS Conference 2024 July 20-26 Munich
Rulan Griesel,1 Amy Pierce,2 Nilay Thakkar,3 Veronica Bainbridge,4 Bronagh Shepherd,4 Konstantinos Angelis,4
Andrew Tomlinson,4 Yash Gandhi,3 Darin Brimhall,5 Daijha Anderson,2 Susan Andrews,3 Carolina Acuipil,2 Cynthia McCoig,6 Mark Baker,7 Max Lataillade,8 Paul Benn1
1ViiV Healthcare, Brentford, UK; 2ViiV Healthcare, Durham, NC, USA; 3GSK, Collegeville, PA, USA; 4GSK, Brentford, UK; 5PPD-Thermo Fisher Scientific, Las Vegas, NV, USA; 6ViiV Healthcare, Madrid, Spain; 7ViiV Healthcare, Nyon, Switzerland; 8ViiV Healthcare, Branford, CT, USA
|
| |
|
|
|
|
|
